Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOSEPH A LASKY

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1598856577
CMS profile
607969
Location
NEW ORLEANS, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$128,336.91

127 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 3; records 101–127 of 127 matching records. This page contains 27 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOSEPH A LASKY

NPI 1598856577 · CMS profile ID 607969

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

NEW ORLEANS, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–127 of 127 matching records. This page contains 27 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1598856577?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOSEPH A LASKY, NPI 1598856577, CMS profile ID 607969. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–127 of 127 matching records. This page contains 27 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1598856577?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). JOSEPH A LASKY, NPI 1598856577, CMS profile ID 607969. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–127 of 127 matching records. This page contains 27 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1598856577?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
JOSEPH A LASKY, NPI 1598856577, CMS profile ID 607969, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–127 of 127 matching records. This page contains 27 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1598856577?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

127 matching records · $128,336.91 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 127 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–127 of 127.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
United Therapeutics Corporation $493.2803/17/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1242527652 CMS
GENZYME CORPORATION $25.3203/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233674840 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $156.3003/06/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1222959141 CMS
United Therapeutics Corporation $303.9702/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1242527052 CMS
United Therapeutics Corporation $24.4902/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242547622 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $66.7902/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222959131 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $641.5002/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1222959143 CMS
United Therapeutics Corporation $3,400.0002/20/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1242546048 CMS
United Therapeutics Corporation $252.9002/19/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1242527584 CMS
United Therapeutics Corporation $65.9802/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242547584 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $22.1102/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222959097 CMS
United Therapeutics Corporation $877.9602/04/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1242527044 CMS
GENZYME CORPORATION $19.1602/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233674834 CMS
United Therapeutics Corporation $6,950.0001/31/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1242548122 CMS
United Therapeutics Corporation $35.6701/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242548166 CMS
United Therapeutics Corporation $50.0001/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242548170 CMS
United Therapeutics Corporation $60.0001/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242550128 CMS
United Therapeutics Corporation $30.6701/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242550136 CMS
United Therapeutics Corporation $368.8301/30/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1242548148 CMS
United Therapeutics Corporation $337.1101/30/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1242548160 CMS
United Therapeutics Corporation $22.8501/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242550138 CMS
Grifols USA, LLC $22.9001/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249587758 CMS
United Therapeutics Corporation $73.8201/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242544886 CMS
United Therapeutics Corporation $3,400.0001/27/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1242549294 CMS
United Therapeutics Corporation $205.2201/16/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1242527116 CMS
United Therapeutics Corporation $105.6501/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242547858 CMS
Actelion Pharmaceuticals US, Inc. $18.3201/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174231035 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $125,666.63 91
PY2020 $46,806.37 50
PY2021 $80,438.16 53
PY2022 $11,768.41 23
PY2023 $4,777.49 32
PY2024 $49,205.19 64
PY2025 $128,336.91 127

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $413,710.23 127
PY2024 Recipient $1,127.85 8
PY2024 Principal investigator $377,167.10 52
PY2023 Principal investigator $372,827.88 37
PY2022 Principal investigator $193,454.73 17
PY2021 Principal investigator $43,904.26 5
PY2020 Principal investigator $23,457.44 3
PY2019 Principal investigator $25,047.51 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

127 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 United Therapeutics Corporation $1,781.25 12/24/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388615
Principal investigator 1 United Therapeutics Corporation $7,060.00 12/24/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388635
Principal investigator 1 United Therapeutics Corporation $1,781.25 12/24/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388645
Principal investigator 1 United Therapeutics Corporation $4,762.50 12/24/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388663
Principal investigator 1 United Therapeutics Corporation $32,929.26 12/10/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388637
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,145.70 12/09/2025 Non-covered Recipient Entity
Admin of the Tulane Educational Fund Tulane University
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220807856
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 12/01/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220679278
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 12/01/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220679280
Principal investigator 1 United Therapeutics Corporation $1,593.75 11/26/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388613
Principal investigator 1 United Therapeutics Corporation $1,593.75 11/26/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388643
Principal investigator 1 United Therapeutics Corporation $6,286.25 11/26/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388669
Principal investigator 1 United Therapeutics Corporation $5,250.00 11/12/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388631
Principal investigator 1 United Therapeutics Corporation $4,125.00 11/12/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388661
Principal investigator 1 United Therapeutics Corporation $5,250.00 11/12/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388665
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,974.00 11/05/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220799177
Principal investigator 1 United Therapeutics Corporation $530.00 11/05/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242388675
Principal investigator 1 United Therapeutics Corporation $14,097.60 11/05/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242388685
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 11/01/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220679274
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 11/01/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220679276
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $888.42 10/31/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220799179
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $371.45 10/31/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220799181
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,005.90 10/28/2025 Non-covered Recipient Entity
The Administrators Of The Tulane Educational Fund
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220792703
Principal investigator 1 United Therapeutics Corporation $7,318.74 10/24/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242388683
Principal investigator 1 United Therapeutics Corporation $500.00 10/22/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388607
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,819.33 10/13/2025 Non-covered Recipient Entity
Admin of the Tulane Educational Fund Tulane University
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220807854
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,749.50 10/03/2025 Non-covered Recipient Entity
The Administrators Of The Tulane Educational Fund
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220792705
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 10/01/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220679270
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 10/01/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220679272
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $16,582.80 09/24/2025 Non-covered Recipient Entity
Admin of the Tulane Educational Fund Tulane University
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220807846
Principal investigator 1 United Therapeutics Corporation $3,812.50 09/10/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388623
Principal investigator 1 United Therapeutics Corporation $1,812.50 09/10/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388647
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,375.36 09/04/2025 Non-covered Recipient Entity
Admin of the Tulane Educational Fund Tulane University
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220807844
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 09/01/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220679258
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 09/01/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220679260
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $28,804.22 08/28/2025 Non-covered Recipient Entity
The Administrators Of The Tulane Educational Fund
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220792701
Principal investigator 1 United Therapeutics Corporation $6,286.25 08/27/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388667
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 08/26/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220679266
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 08/26/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220679268
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $11,497.50 08/18/2025 Non-covered Recipient Entity
The Administrators Of The Tulane Educational Fund
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220792699
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,225.00 08/06/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220799171
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 08/01/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220679254
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 08/01/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220679256
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 07/28/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220679262
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 07/28/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220679264
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,358.76 07/28/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220799173
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $538.98 07/28/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220799175
Principal investigator 1 United Therapeutics Corporation $16,053.97 07/25/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242388689
Principal investigator 1 United Therapeutics Corporation $500.00 07/23/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388605
Principal investigator 1 United Therapeutics Corporation $7,411.25 07/23/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388671
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $158.40 07/13/2025 Non-covered Recipient Entity
Admin of the Tulane Educational Fund Tulane University
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220807852
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1.60 07/10/2025 Non-covered Recipient Entity
Admin of the Tulane Educational Fund Tulane University
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220807840
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,420.32 07/10/2025 Non-covered Recipient Entity
Admin of the Tulane Educational Fund Tulane University
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220807842
Principal investigator 1 United Therapeutics Corporation $3,375.00 07/08/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388621
Principal investigator 1 United Therapeutics Corporation $3,375.00 07/08/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388657
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 07/01/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220679250
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 07/01/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220679252
Principal investigator 1 United Therapeutics Corporation $6,185.00 06/25/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388633
Principal investigator 1 United Therapeutics Corporation $1,937.50 06/25/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388651
Principal investigator 1 United Therapeutics Corporation $2,812.50 06/11/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388619
Principal investigator 1 United Therapeutics Corporation $2,812.50 06/11/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388655
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,299.00 06/04/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220799169
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 06/01/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220679232
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 06/01/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220679234
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $19,325.70 06/01/2025 Non-covered Recipient Entity
The Administrators Of The Tulane Educational Fund
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220792697
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $170.40 06/01/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220799165
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $52.40 06/01/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220799167
Principal investigator 1 Boehringer Ingelheim International GmbH $81.62 05/27/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220679242
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 05/27/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220679244
Principal investigator 1 Boehringer Ingelheim International GmbH $10.08 05/27/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220679246
Principal investigator 1 Boehringer Ingelheim International GmbH $9.00 05/27/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220679248
Principal investigator 1 United Therapeutics Corporation $4,530.00 05/21/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388625
Principal investigator 1 United Therapeutics Corporation $9,650.00 05/21/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388673
Principal investigator 1 United Therapeutics Corporation $2,431.44 05/14/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242388677
Principal investigator 1 United Therapeutics Corporation $3,300.00 05/14/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242388679
Principal investigator 1 United Therapeutics Corporation $4,980.00 05/14/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242388681
Principal investigator 1 United Therapeutics Corporation $14,520.00 05/14/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242388687
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,564.90 05/07/2025 Non-covered Recipient Entity
Admin of the Tulane Educational Fund Tulane University
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220807850
Principal investigator 1 United Therapeutics Corporation $1,593.75 05/07/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388611
Principal investigator 1 United Therapeutics Corporation $4,530.00 05/07/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388627
Principal investigator 1 United Therapeutics Corporation $5,062.50 05/07/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388629
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 05/01/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220679228
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 05/01/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220679230
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 04/23/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220679236
Principal investigator 1 Boehringer Ingelheim International GmbH $1.68 04/23/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220679238
Principal investigator 1 Boehringer Ingelheim International GmbH $1.50 04/23/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220679240
Principal investigator 1 United Therapeutics Corporation $1,593.75 04/23/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388641
Principal investigator 1 United Therapeutics Corporation $3,625.00 04/23/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388659
Principal investigator 1 United Therapeutics Corporation $937.50 04/09/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388609
Principal investigator 1 United Therapeutics Corporation $937.50 04/09/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388639
Principal investigator 1 United Therapeutics Corporation $2,437.50 04/09/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388653
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $14.00 04/02/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220799183
Principal investigator 1 Boehringer Ingelheim International GmbH $37.66 04/01/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220679224
Principal investigator 1 Boehringer Ingelheim International GmbH $37.66 04/01/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220679226
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20.53 04/01/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220799155
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $313.56 04/01/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220799161
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $124.38 04/01/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220799163
Principal investigator 1 Boehringer Ingelheim International GmbH $11.66 03/25/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220679222
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,942.40 03/19/2025 Non-covered Recipient Entity
The Administrators Of The Tulane Educational Fund
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220792695
Principal investigator 1 Boehringer Ingelheim International GmbH $103.87 03/01/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220679290
Principal investigator 1 Boehringer Ingelheim International GmbH $11.57 03/01/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220679292
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22.00 03/01/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220799153
Principal investigator 1 United Therapeutics Corporation $5,968.75 02/26/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388595
Principal investigator 1 United Therapeutics Corporation $6,062.50 02/26/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388601
Principal investigator 1 United Therapeutics Corporation $1,875.00 02/26/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388617
Principal investigator 1 United Therapeutics Corporation $1,875.00 02/26/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388649
Principal investigator 1 Boehringer Ingelheim International GmbH $23.32 02/25/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220679214
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 02/25/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220679216
Principal investigator 1 Boehringer Ingelheim International GmbH $5.04 02/25/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220679218
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 02/25/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220679220
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $11,035.80 02/14/2025 Non-covered Recipient Entity
The Administrators Of The Tulane Educational Fund
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220792693
Principal investigator 1 United Therapeutics Corporation $3,093.75 02/12/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388591
Principal investigator 1 United Therapeutics Corporation $5,968.75 02/12/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388593
Principal investigator 1 United Therapeutics Corporation $3,051.42 02/12/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388597
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,564.90 02/07/2025 Non-covered Recipient Entity
Admin of the Tulane Educational Fund Tulane University
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220807834
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,205.54 02/06/2025 Non-covered Recipient Entity
Admin of the Tulane Educational Fund Tulane University
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220807838
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $585.00 02/03/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220799159
Principal investigator 1 Boehringer Ingelheim International GmbH $11.57 02/01/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220679286
Principal investigator 1 Boehringer Ingelheim International GmbH $103.87 02/01/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220679288
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22.00 02/01/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220799151
Principal investigator 1 United Therapeutics Corporation $3,093.75 01/29/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388599
Principal investigator 1 United Therapeutics Corporation $6,700.00 01/29/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388603
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,708.60 01/21/2025 Non-covered Recipient Entity
Admin of the Tulane Educational Fund Tulane University
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220807848
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,129.80 01/08/2025 Non-covered Recipient Entity
Admin of the Tulane Educational Fund Tulane University
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220807836
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,994.00 01/06/2025 Non-covered Recipient Entity
The Administrators Of The Tulane Educational Fund
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220792691
Principal investigator 1 Boehringer Ingelheim International GmbH $11.57 01/01/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220679282
Principal investigator 1 Boehringer Ingelheim International GmbH $103.87 01/01/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220679284
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22.00 01/01/2025 Non-covered Recipient Entity
Tulane University Hospital And Clinic
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220799149